Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: Dopamine targets their common pathways

Human Reproduction

Volumn 25, Issue 3, 2010, Pages 757-767

  Chen, Shee Uan ^a   Chou, Chia Hung ^a   Lin, Chung Wu ^a   Lee, Hsinyu ^a   Wu, Jiahn Chun ^a   Lu, Hsin Fen ^b   Chen, Chin Der ^a   Yang, Yu Shih ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

IL 8; Ovarian hyperstimulation syndrome; Signal pathway; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CADHERIN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHORIONIC GONADOTROPIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; OCCLUDIN; PLATELET DERIVED GROWTH FACTOR; RHO FACTOR; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; XANTHOPHYLL;

ACTIN POLYMERIZATION; ARTICLE; ASCITES; CELL JUNCTION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS LUTEUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; OVARY FOLLICLE FLUID; OVARY HYPERSTIMULATION; PERMEABILITY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TRANSACTIVATION;

EID: 76749084251     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dep432     Document Type: Article

References (46)

1. Alvarez C, Mart́i-Bonmat́i L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, Simón C, Pellicer A. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007a;92:2931-2937.
2. Alvarez C, Alonso-Muriel I, Garcia G, Crespo J, Bellver J, Simon C, Pellicer A. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007b;22:3210-3214.
3. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569-574. (Pubitemid 32448324)
4. Borenstein R, Elhalah U, Lunenfeld B, Schwartz ZS. Severe ovarian hyperstimulation syndrome: a reevaluated therapeutic approach. Fertil Steril 1989;51:791-795.
5. Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res 2009;69:3727-3730.
6. Chen SU, Chen CD, Yang YS. Ovarian hyperstimulation syndrome (OHSS): new strategies of prevention and treatment. J Formos Med Assoc 2008a;107:509-512.
7. Chen SU, Chou CH, Lee HY, Ho CH, Lin CW, Yang YS. Lysophosphatidic acid up-regulates expression of interleukin-8 and-6 in human granulosa-lutein cells through LPA receptors and NF-lB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2008b;93:935-943.
8. Chen SU, Lee HY, Chang DY, Chou CH, Chang CY, Chao K-H, Lin C-W, Yang YS. Lysophosphatidic acid mediates interleukin-8 expression in human endometrial stromal cells through its receptor and nuclear factor-kB dependent pathway: a possible role in angiogenesis of endometrium and placenta. Endocrinology 2008c;149:5888-5896.
9. Chiba H, Sawada N, Saito T. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006;147:694-699.
10. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008; 121:2115-2122.
11. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003; 9:77-96.
12. Eiselein L, Wilson DW, Lamé MW, Rutledge JC. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol 2007;292:H2745-H2753.
13. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome-views and ideas. Hum Reprod 1997;12:1129-1137.
14. Essler M, Retzer M, Bauer M, Heemskerk JW, Aepfelbacher M, Siess W. Mildly oxidized low density lipoprotein induces contraction of human endothelial cells through activation of Rho/Rho kinase and inhibition of myosin light chain phosphatase. J Biol Chem 1999;274:30361-30364.
15. Fainaru O, Adini I, Benny O, Bazinet L, Pravda E, D'Amato R, Folkman J. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J 2008a;22:3728-3735.
16. Fainaru O, Hornstein MD, Folkman J. Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation syndrome in a murine model. Fertil Steril 2009;92:1701-1705.
17. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohi J, Simon C, Pellicer A. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400-5411.
18. Katz Z, Lancet M, Borenstein R, Chemke J. Absence of teratogenicity of indomethacin in ovarian hyperstimulation syndrome. Int J Fertil 1984; 29:186-188.
19. Levin ER, Rosen GF, Cassidenti DL, Yee B, Meldrum D, Wisot A, Pedram A. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome. J Clin Invest 1998;102:1978-1985.
20. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008;7:3670-3684.
21. Manau D, Fábregues F, Peñarrubia J, Creus M, Carmona F, Casals G, Jiménez W, Balasch J. Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF. Hum Reprod 2007;22:669-675.
22. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT, Robertson DM. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-236.
23. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006;354:2621-2622.
24. Nargund G, Hutchison L, Scaramuzzi R, Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online 2007;14:682-685.
25. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, Marme D, Breckwoldt M. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80:1967-1971.
26. Petreaca ML, Yao M, Liu Y, Defea K, Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by Interleukin-8 (IL-8/ CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 2007;18:5014-5023.
27. Plaisier M, Rodrigues S, Willems F, Koolwijk P, van Hinsbergh VW, Helmerhorst FM. Different degrees of vascularization and their relationship to the expression of vascular endothelial growth factor, placental growth factor, angiopoietins, and their receptors in first-trimester decidual tissues. Fertil Steril 2007;88:176-187.
28. Plaisier M, Dennert I, Rost E, Koolwijk P, van Hinsbergh VW, Helmerhorst FM. Decidual vascularization and the expression of angiogenic growth factors and proteases in first trimester spontaneous abortions. Hum Reprod 2009;24:185-197.
29. Rodewald M, Herr D, Fraser HM, Hack G, Kreienberg R, Wulff C. Regulation of tight junction proteins occludin and claudin 5 in the primate ovary during the ovulatory cycle and after inhibition of vascular endothelial growth factor. Mol Hum Reprod 2007;13:781-789.
30. Rodewald M, Herr D, Duncan WC, Fraser HM, Hack G, Konrad R, Gagsteiger F, Kreienberg R, Wulff C. Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum Reprod 2009;24:1191-1199.
31. Schenker JG, Polishuk WZ. The role of prostaglandins in ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1976; 6:47-52.
32. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril 1978;30:255-268.
33. Shimizu S, Tahara M, Ogata S, Hashimoto K, Morishige K, Tasaka K, Murata Y. Involvement of nuclear factor-kB activation through RhoA/ Rho-kinase pathway in LPS-induced IL-8 production in human cervical stromal cells. Mol Hum Reprod 2007;13:181-187.
34. Stanek MB, Borman SM, Molskness TA, Larson JM, Stouffer RL, Patton PE. Insulin and IGF stimulation of VEGF production by luteinized granulosa cells: comparison between PCOS and non-PCOS women. J Clin Endocrinol Metab 2007;92:2726-2733.
35. Stocco C, Telleria C, Gibori G. The molecular control of corpus luteum formation, function, and regression. Endocr Rev 2007;28:117-149.
36. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004; 23:9247-9258.
37. Tamilarasan KP, Kolluru GK, Rajaram M, Indhumathy M, Saranya R, Chatterjee S. Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells. BMC Cell Biol 2006;7:17.
38. Tokumura A, Miyake M, Nishioka Y, Yamano S, Aono T, Fukuzawa K. Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of in vitro fertilization patients. Biol Reprod 1999; 61:195-199.
39. van de Lagemaat R, Timmers CM, Kelder J, van Koppen C, Mosselman S, Hanssen RG. Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. Hum Reprod 2009;24:640-648.
40. van den Driesche S, Myers M, Gay E, Thong KJ, Duncan WC. HCG up-regulates hypoxia inducible factor-1 alpha in luteinized granulosa cells: implications for the hormonal regulation of vascular endothelial growth factor A in the human corpus luteum. Mol Hum Reprod 2008; 14:455-464.
41. Vardhana PA, Julius MA, Pollak SV, Lustbader EG, Trousdale RK, Lustbader JW. A unique hCG-antagonist suppresses ovarian hyperstimulation syndrome (OHSS) in rats. Endocrinology 2009; 150:3807-3814.
42. Varnagy A, Bodis J, Manfai Z, Wilhelm F, Busznyak C, Koppan M. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril 2009; Mar 2 [Epub ahead of print].
43. Velez DR, Fortunato SJ, Morgan N, Edwards TL, Lombardi SJ, Williams SM, Menon R. Patterns of cytokine profiles differ with pregnancy outcome and ethnicity. Hum Reprod 2008;23:1902-1909.
44. Villasante A, Pacheco A, Ruiz A, Pellicer A, Garcia-Velasco JA. Vascular endothelial cadherin regulates vascular permeability: Implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2007; 92:314-321.
45. Villasante A, Pacheco A, Pau E, Ruiz A, Pellicer A, Garcia-Velasco JA. Soluble vascular endothelial-cadherin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. Hum Reprod 2008;23:662-667.
46. Wu X, Shen H, Yu L, Peng M, Lai WS, Ding YL. Corticotropin-releasing hormone activates connexin 43 via activator protein-1 transcription factor in human myometrial smooth muscle cells. Am J Physiol Endocrinol Metab 2007;293:E1789-E1794.